Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor

Archives of Dermatology

Volumn 144, Issue 10, 2008, Pages 1400-1402

  Battistella, Maxime ^b   Frémont, Guillemette ^a   Vignon Pennamen, Marie Dominique ^b   Gornet, Jean Marc ^b   Dubertret, Louis ^b   Viguier, Manuelle ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYTARABINE; DOXORUBICIN; FLUOROURACIL; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ADULT; CANCER CHEMOTHERAPY; CASE REPORT; DOSE RESPONSE; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN MANIFESTATION; STOMATITIS; TREATMENT OUTCOME;

BIOPSY, NEEDLE; DRUG ERUPTIONS; ERYTHEMA; FOLLOW-UP STUDIES; FOOT DERMATOSES; GASTROINTESTINAL STROMAL TUMORS; HAND DERMATOSES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYLORIC ANTRUM; PYRIMIDINES; RISK ASSESSMENT; STOMACH NEOPLASMS; SYNDROME;

EID: 54349114669     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.10.1400     Document Type: Letter

References (5)

1. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5(3):228-231.
2. Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;141(3):368-370.
3. Deguchi N, Kawamura T, Shimizu A, et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. Br J Dermatol. 2006;154(6):1216-1218.
4. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500.
5. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007;29(7):1338-1353.